Shares of Quest Diagnostics (DGX) surged 5.09% during intraday trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.

The diagnostic information services provider reported quarterly revenue of $2.81 billion and adjusted earnings per share of $2.42, both exceeding analyst consensus estimates. Furthermore, the company issued 2026 revenue guidance in the range of $11.7 billion to $11.82 billion and adjusted EPS guidance of $10.50 to $10.70, which also topped market expectations, driven by strong demand for laboratory tests.

In tandem with the robust financial performance, Quest Diagnostics announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking 15 consecutive years of dividend growth, and authorized an additional $1 billion for its share repurchase program, significantly boosting shareholder returns.